{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:44:58Z","timestamp":1787010298775,"version":"build-2736575974"},"reference-count":122,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n                    <jats:title>Learning Objectives:<\/jats:title>\n                    <jats:p>After studying this article, the participant should be able to: 1. Summarize the changes to the American Joint Committee on Cancer Eighth Edition Melanoma Staging System. 2. List advances in genetic, molecular, and histopathologic melanoma diagnosis and prognostication. 3. Recommend sentinel lymph node biopsy and appropriate surgical margins based on individualized patient needs. 4. Recognize the currently available treatments for in-transit metastasis and advanced melanoma. 5. Describe current and future therapies for melanoma with distant visceral or brain metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>Strides in melanoma surveillance, detection, and treatment continue to be made. The American Joint Committee on Cancer Eighth Edition Cancer Staging System has improved risk stratification of patients, introduced new staging categories, and resulted in stage migration of patients with improved outcomes. This review summarizes melanoma advances of the recent years with an emphasis on the surgical advances, including techniques and utility of sentinel node biopsy, controversies in melanoma margin selection, and the survival impact of time-to-treatment metrics. Once a disease manageable only with surgery, a therapeutic paradigm shift has given a more promising outlook to melanoma patients at any stage. Indeed, a myriad of novel, survival-improving immunotherapies have been introduced for metastatic melanoma and more recently in the high-risk adjuvant setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/prs.0000000000004571","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T19:07:54Z","timestamp":1532632074000},"page":"202e-216e","source":"Crossref","is-referenced-by-count":58,"title":["Malignant Melanoma: Diagnostic and Management Update"],"prefix":"10.1097","volume":"142","author":[{"given":"Thomas","family":"Knackstedt","sequence":"first","affiliation":[{"name":"From the Departments of Plastic Surgery and Dermatology, Cleveland Clinic Foundation."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Knackstedt","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic Surgery and Dermatology, Cleveland Clinic Foundation."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Couto","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic Surgery and Dermatology, Cleveland Clinic Foundation."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gastman","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic Surgery and Dermatology, Cleveland Clinic Foundation."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jamadermatol.2013.5517","article-title":"Mobile applications in dermatology.","volume":"149","author":"Brewer","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/jamadermatol.2013.2382","article-title":"Diagnostic inaccuracy of smartphone applications for melanoma detection.","volume":"149","author":"Wolf","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jaad.2015.02.1138","article-title":"Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches.","volume":"72","author":"March","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature21056","article-title":"Dermatologist-level classification of skin cancer with deep neural networks.","volume":"542","author":"Esteva","year":"2017","journal-title":"Nature"},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.134.1.103-a","article-title":"The \u2018ugly duckling\u2019 sign: Identification of the common characteristics of nevi in an individual as a basis for melanoma screening.","volume":"134","author":"Grob","year":"1998","journal-title":"Arch Dermatol"},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bjps.2006.10.003","article-title":"Assessment of nurse-led screening of pigmented lesions using SIAscope.","volume":"60","author":"Govindan","year":"2007","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1365-2133.2007.07932.x","article-title":"The use of a spectrophotometric intracutaneous analysis device in the real-time diagnosis of melanoma in the setting of a melanoma screening clinic.","volume":"156","author":"Haniffa","year":"2007","journal-title":"Br J Dermatol"},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00008390-200012000-00008","article-title":"Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind multispectral digital dermoscope.","volume":"10","author":"Gutkowicz-Krusin","year":"2000","journal-title":"Melanoma Res"},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/08941939309141189","article-title":"A study of the electrical bio-impedance of tumors.","volume":"6","author":"Morimoto","year":"1993","journal-title":"J Invest Surg"},{"key":"R10-20230908","first-page":"111","article-title":"Breast cancer screening by impedance measurements.","volume":"2","author":"Piperno","year":"1990","journal-title":"Front Med Biol Eng"},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/bjd.13121","article-title":"Clinical performance of the Nevisense system in cutaneous melanoma detection: An international, multicentre, prospective and blinded clinical trial on efficacy and safety.","volume":"171","author":"Malvehy","year":"2014","journal-title":"Br J Dermatol"},{"key":"R12-20230908","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma.","volume":"7","author":"Weinstein","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/DAD.0b013e31828a2ec5","article-title":"Cutaneous malignant melanoma: Update on diagnostic and prognostic biomarkers.","volume":"36","author":"Abbas","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0560.2007.00891.x","article-title":"Immunohistochemical characteristics of melanoma.","volume":"35","author":"Ohsie","year":"2008","journal-title":"J Cutan Pathol"},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cll.2017.06.002","article-title":"Molecular melanoma diagnosis update: Gene fusion, genomic hybridization, and massively parallel short-read sequencing.","volume":"37","author":"Lang","year":"2017","journal-title":"Clin Lab Med"},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/DAD.0000000000000380","article-title":"Fluorescence in situ hybridization for melanoma diagnosis: A review and a reappraisal.","volume":"38","author":"Ferrara","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.","volume":"42","author":"Clarke","year":"2015","journal-title":"J Cutan Pathol"},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.","volume":"72","author":"Gerami","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-017-0520-1","article-title":"Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.","volume":"10","author":"Hsueh","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molonc.2015.12.008","article-title":"Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.","volume":"10","author":"Huang","year":"2016","journal-title":"Mol Oncol"},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials.","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high risk stage II\/III melanoma.","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"R27-20230908","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2017.08.039","article-title":"Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.","volume":"78","author":"Conic","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R28-20230908","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2016.08.014","article-title":"Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival.","volume":"67","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Cancer"},{"key":"R29-20230908","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1245\/s10434-017-6146-2","article-title":"Wait times for melanoma surgery: Is there an association with overall survival?","volume":"25","author":"Crawford","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R30-20230908","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: A randomised, multicentre trial.","volume":"378","author":"Gillgren","year":"2011","journal-title":"Lancet"},{"key":"R31-20230908","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archsurg.142.9.885","article-title":"Excision margins for primary cutaneous melanoma: Updated pooled analysis of randomized controlled trials.","volume":"142","author":"Lens","year":"2007","journal-title":"Arch Surg"},{"key":"R32-20230908","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1245\/s10434-015-4942-0","article-title":"The association between excision margins and local recurrence in 11,290 thin (T1) primary cutaneous melanomas: A case-control study.","volume":"23","author":"MacKenzie Ross","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R33-20230908","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.sla.0000152014.89434.96","article-title":"Histopathologic excision margin affects local recurrence rate: Analysis of 2681 patients with melanomas < or =2 mm thick.","volume":"241","author":"McKinnon","year":"2005","journal-title":"Ann Surg"},{"key":"R34-20230908","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ctrv.2015.10.013","article-title":"Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.","volume":"42","author":"Wheatley","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R35-20230908","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1245\/s10434-012-2543-8","article-title":"1 or 2 cm margins of excision for T2 melanomas: Do they impact recurrence or survival?","volume":"20","author":"Hudson","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R36-20230908","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1245\/s10434-016-5167-6","article-title":"Is a wider margin (2 cm vs. 1 cm) for a 1.01-2.0 mm melanoma necessary?","volume":"23","author":"Doepker","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R37-20230908","first-page":"147","article-title":"Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning.","volume":"28","author":"Robinson","year":"1977","journal-title":"Surg Forum"},{"key":"R38-20230908","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma.","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"R39-20230908","first-page":"967","article-title":"TRUE SIGNIFICANCE and real incidence of reactions following clinical use of antibiotics; panel discussion.","volume":"3","year":"1955","journal-title":"Antibiot Annu"},{"key":"R40-20230908","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1245\/ASO.2003.06.007","article-title":"Sentinel lymph node biopsy for head and neck melanomas.","volume":"10","author":"Chao","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"R41-20230908","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.2003.07.170","article-title":"Clinical outcome of stage I\/II melanoma patients after selective sentinel lymph node dissection: Long-term follow-up results.","volume":"21","author":"Vuylsteke","year":"2003","journal-title":"J Clin Oncol"},{"key":"R42-20230908","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1245\/s10434-007-9433-5","article-title":"Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma.","volume":"14","author":"Carac\u00f2","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R43-20230908","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1245\/s10434-006-9066-0","article-title":"Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.","volume":"13","author":"Nowecki","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R44-20230908","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1200\/JCO.2006.06.3198","article-title":"Sentinel and nonsentinel node status in stage IB and II melanoma patients: Two-step prognostic indicators of survival.","volume":"24","author":"Cascinelli","year":"2006","journal-title":"J Clin Oncol"},{"key":"R45-20230908","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0b013e3181855718","article-title":"Regional recurrence after negative sentinel lymph node biopsy for melanoma.","volume":"248","author":"Carlson","year":"2008","journal-title":"Ann Surg"},{"key":"R46-20230908","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/sj.bjc.6604407","article-title":"The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma: A retrospective analysis of 392 cases.","volume":"98","author":"Guggenheim","year":"2008","journal-title":"Br J Cancer"},{"key":"R47-20230908","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","article-title":"Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.","volume":"148","author":"Jones","year":"2013","journal-title":"JAMA Surg"},{"key":"R48-20230908","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1245\/s10434-015-4912-6","article-title":"Predictors and survival impact of false-negative sentinel nodes in melanoma.","volume":"23","author":"Lee","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R49-20230908","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1245\/s10434-009-0857-y","article-title":"Who is to blame for false-negative sentinel node biopsies in melanoma?","volume":"17","author":"Sondak","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R50-20230908","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1245\/s10434-013-2905-x","article-title":"Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma.","volume":"20","author":"Gilmore","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R51-20230908","first-page":"12","article-title":"Near-infrared fluorescence imaging in humans with indocyanine green: A review and update.","volume":"2","author":"Marshall","year":"2010","journal-title":"Open Surg Oncol J"},{"key":"R52-20230908","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jso.23045","article-title":"Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer.","volume":"106","author":"Fujisawa","year":"2012","journal-title":"J Surg Oncol"},{"key":"R53-20230908","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/PRS.0000000000000006","article-title":"Indocyanine green SPY elite-assisted sentinel lymph node biopsy in cutaneous melanoma.","volume":"133","author":"Korn","year":"2014","journal-title":"Plast Reconstr Surg"},{"issue":"Suppl 3","key":"R54-20230908","doi-asserted-by":"crossref","first-page":"S1271","DOI":"10.1245\/s10434-015-4743-5","article-title":"Current trends and emerging future of indocyanine green usage in surgery and oncology: An update.","volume":"22","author":"Zelken","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R55-20230908","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.bjps.2007.12.074","article-title":"Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: Preliminary experience.","volume":"62","author":"Fujiwara","year":"2009","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R56-20230908","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1245\/s10434-009-0858-x","article-title":"Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.","volume":"17","author":"Scoggins","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R57-20230908","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma.","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"R58-20230908","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma.","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"R59-20230908","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): A multicentre, randomised, phase 3 trial.","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"R60-20230908","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma.","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"R61-20230908","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1245\/s10434-012-2652-4","article-title":"Evidence for a better nodal staging system for melanoma: The clinical relevance of metastatic disease confined to the sentinel lymph nodes.","volume":"20","author":"Reintgen","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R62-20230908","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamasurg.2013.3044","article-title":"Staging of regional lymph nodes in melanoma: A case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system.","volume":"148","author":"Leung","year":"2013","journal-title":"JAMA Surg"},{"key":"R63-20230908","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dth.12544","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma.","volume":"30","author":"Fioranelli","year":"2017","journal-title":"Dermatol Ther"},{"key":"R64-20230908","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1245\/s10434-013-2977-7","article-title":"Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?","volume":"20","author":"Fadaki","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R65-20230908","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1245\/s10434-013-3464-x","article-title":"Age as a predictor of sentinel node metastasis among patients with localized melanoma: An inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.","volume":"21","author":"Balch","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R66-20230908","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690\/S9111\/C9190.","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"R67-20230908","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2013.53.1590","article-title":"Southwest Oncology Group S0008: A phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma. An intergroup study of cancer and leukemia Group B, Children\u2019s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.","volume":"32","author":"Flaherty","year":"2014","journal-title":"J Clin Oncol"},{"key":"R68-20230908","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors.","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"R69-20230908","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R70-20230908","doi-asserted-by":"crossref","first-page":"83280","DOI":"10.18632\/oncotarget.21059","article-title":"Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF\/MEK inhibitors in cancer patients: A meta-analysis.","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"R72-20230908","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"R73-20230908","article-title":"Association of PD-L1 expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.","author":"Wongchenko","journal-title":"Pigment Cell Melanoma Res"},{"key":"R74-20230908","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"R75-20230908","doi-asserted-by":"crossref","first-page":"e0188602","DOI":"10.1371\/journal.pone.0188602","article-title":"Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.","volume":"12","author":"Gaiser","year":"2017","journal-title":"PLoS One"},{"key":"R76-20230908","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade.","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R77-20230908","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents.","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"R78-20230908","first-page":"5671","article-title":"Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.","volume":"14","author":"Stucci","year":"2017","journal-title":"Oncol Lett"},{"key":"R79-20230908","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R80-20230908","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study.","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"R81-20230908","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"R82-20230908","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jss.2016.04.029","article-title":"Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: A systematic review and meta-analysis of current published literature.","volume":"203","author":"Anwar","year":"2016","journal-title":"J Surg Res"},{"key":"R83-20230908","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.humpath.2014.07.014","article-title":"Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.","volume":"45","author":"Fisher","year":"2014","journal-title":"Hum Pathol"},{"key":"R84-20230908","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma.","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"key":"R85-20230908","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1188\/17.CJON.699-709","article-title":"MAPK pathway-targeted therapies: Care and management of unique toxicities in patients with advanced melanoma.","volume":"21","author":"Rubin","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"R86-20230908","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma.","volume":"22","author":"Daud","year":"2017","journal-title":"Oncologist"},{"key":"R87-20230908","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma.","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"R88-20230908","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/jid.2013.462","article-title":"Melanoma patients under vemurafenib: Prospective follow-up of melanocytic lesions by digital dermoscopy.","volume":"134","author":"Perier-Muzet","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R89-20230908","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R90-20230908","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial.","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"R91-20230908","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","article-title":"The use of interferon in melanoma patients: A systematic review.","volume":"26","author":"Di Trolio","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"R92-20230908","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R93-20230908","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R94-20230908","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: Incidence, prognosis, and the role of lymphadenectomy.","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R95-20230908","doi-asserted-by":"crossref","first-page":"e016816","DOI":"10.1136\/bmjopen-2017-016816","article-title":"Protocol for the TIDAL Melanoma Study: Topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases. A phase II, single centre, randomised, pilot study.","volume":"7","author":"Read","year":"2017","journal-title":"BMJ Open"},{"key":"R96-20230908","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2015.06.060","article-title":"100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series.","volume":"73","author":"Shi","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R97-20230908","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2016.01.004","article-title":"Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream.","volume":"2","author":"Leventhal","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R98-20230908","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"R99-20230908","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy.","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"R100-20230908","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.","author":"Chesney","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R101-20230908","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"R102-20230908","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R103-20230908","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial.","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"key":"R104-20230908","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R105-20230908","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R106-20230908","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"R107-20230908","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R108-20230908","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"R109-20230908","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R110-20230908","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma.","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R111-20230908","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14737140.2017.1374177","article-title":"Binimetinib for the treatment of NRAS-mutant melanoma.","volume":"17","author":"Queirolo","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"R112-20230908","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial.","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"R113-20230908","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-69222-7_1","article-title":"Brain metastases: Epidemiology and pathophysiology.","volume":"136","author":"Sul","year":"2007","journal-title":"Cancer Treat Res"},{"key":"R114-20230908","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"R115-20230908","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/bjc.2011.178","article-title":"Central nervous system failure in melanoma patients: Results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens.","volume":"104","author":"Chiarion-Sileni","year":"2011","journal-title":"Br J Cancer"},{"key":"R116-20230908","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"R117-20230908","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma.","volume":"7","author":"Sandru","year":"2014","journal-title":"J Med Life"},{"key":"R118-20230908","first-page":"936","article-title":"Outcome variation among \u201cradioresistant\u201d brain metastases treated with stereotactic radiosurgery.","volume":"56","author":"Chang","year":"2005","journal-title":"Neurosurgery"},{"key":"R119-20230908","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3340\/jkns.2013.54.2.107","article-title":"The usefulness of stereotactic radiosurgery for radioresistant brain metastases.","volume":"54","author":"Kim","year":"2013","journal-title":"J Korean Neurosurg Soc"},{"key":"R120-20230908","first-page":"e1511","article-title":"Stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone in melanoma brain metastases.","volume":"9","author":"Nguyen","year":"2017","journal-title":"Cureus"},{"key":"R121-20230908","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial.","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"R122-20230908","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study.","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"R123-20230908","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial.","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006534-201808000-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:05:16Z","timestamp":1694185516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006534-201808000-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000004571","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}